Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF35700 Receptor Occupancy PET Study in Schizophrenia
NCT02333487Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lu af35700 in schizophrenia (3 arms), sponsored by Lundbeck. Primary endpoints: Emax D1 Dopamine Receptor Occupancy, EC50 D1 Dopamine Receptor Occupancy and 4 more. Started Dec 2014; status: completed.
02
Drugs
lu af35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02333487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333487.